SEMA3C and prostate cancer: The ability of semaphorin 3C to promote intratumoral androgen synthesis was confirmed by the authors in castration-resistant prostate cancer patients by conferring continued growth of prostate tumors under androgen deprivation therapy associated with Semaphorin 3C upregulation [109].